In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Challenge Of Pricing Amgen's Newly Approved Prolia

Executive Summary

Amgen's first-in-class drug Prolia is burdened with a high price point as it joins a competitive and price-sensitive market for osteoporosis drugs. But Amgen’s decision to value the drug at a premium, effectively sacrificing the first-line treatment market for osteoporosis, to maintain Prolia’s potential in oncology is telling. Certainly, pricing across multiple indications is becoming an increasing challenge for drugmakers, who are under growing scrutiny from payors even as they aim to push drugs to market quickly in one indication before expanding into other arenas. The issue becomes a particularly challenging tight rope to walk when as is true for Prolia one of the indications is in primary care and the other is in a high-priced specialty field such as oncology.

You may also be interested in...

TransEnterix Names New CFO, Reports Negative Q2 Earnings Amid Challenging Times

TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.

Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

CureVac Launches IPO, Adds To Big 2020 Cash Haul

CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts